Stella Chemifa Of Japan To Commercialize Boron Isotope Cancer Treatment System
This article was originally published in PharmAsia News
Executive Summary
Osaka-based Stella Chemifa plans to commercialize its boron neutron capture treatment by 2011. BNCT uses neutron rays to radiate cancer tissues embedded with boron isotope chemical, and selectively kill cancer cells. By only destroying targeted cells and having no impact to other cells, BNCT can be used to treat malignant cancers such as brain tumors, mesothelioma, lung and liver cancer. Starting in 2009, clinical trials will be conducted jointly with Kyodo University's Research Reactor Institute. (Click here for more - Japanese language
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.